EGR1 drives sex-differences in glioblastoma tumorigenicity

Abstract excerpt

Although progress has been made in treating glioblastoma (GBM), with fewer than 5% of patients surviving more than 5 years after diagnosis. For reasons that are not well understood, females are roughly 60% as likely as males to develop GBM, and female patients consistently respond better to treatment than do males. Understanding the molecular etiology of these sex differences in tumor progression and resiliency to...

Topics

Open a Topic to create a Post that cites this publication.

• Brain Neoplasms
• Gene Expression Regulation, Neoplastic
• Glioblastoma
• Phenotype
• Protein Degradation and Inhibitors
• Sex Characteristics
• Tumor Microenvironment
• Ubiquitin and proteasome pathways

Identifiers and source

Literature Corpus work

2f766a92-2d47-5ca4-85c6-baa06fdca9ec

DOI

10.1101/2025.05.16.654616